공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

암치료용 생물학적 제제 : 기술과 세계 시장

Biological Therapies for Cancer: Technologies and Global Markets

리서치사 BCC Research
발행일 2021년 09월 상품 코드 1029575
페이지 정보 영문 258 Pages
가격
US $ 5,500 ₩ 6,586,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄기능에 제약은 없으나 원칙적으로 허용된 인쇄횟수는 1회이며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,600 ₩ 7,903,000 PDF (2-5 Users) help
동일 사업장 내 5명까지 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄기능에 제약은 없으나 원칙적으로 허용된 인쇄횟수는 5회까지이며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,920 ₩ 9,484,000 PDF (Site License) help
동일 사업장 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 9,504 ₩ 11,381,000 PDF (Enterprise License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


암치료용 생물학적 제제 : 기술과 세계 시장 Biological Therapies for Cancer: Technologies and Global Markets
발행일 : 2021년 09월 페이지 정보 : 영문 258 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 암치료용 생물학적 제제 시장 규모는 예측 기간 중 13.0%의 CAGR로 추이하며, 2021년 775억 달러에서 2026년에는 1430억 달러 규모로 성장할 것으로 예측됩니다.

약제 클래스별로는 모노클로널 항체 부문이 같은 기간 중 12.8%의 CAGR로 추이하며, 2021년 680억 달러에서 2026년에는 1241억 달러 규모로 성장할 전망입니다. 또한 CAR-T세포 부문이 37.5%의 CAGR로 추이하며, 2021년 15억 달러에서 2026년에는 73억 달러 규모로 성장할 것으로 예측됩니다.

세계의 암치료용 생물학적 제제 시장을 조사했으며, 시장의 정의와 개요, 임상 개요, 역학적 동향, 주요 출시 제품, 임상시험·파이프라인의 동향, 신종 코로나바이러스 감염증(COVID-19)의 영향, 시장 규모의 추이·예측, 제품 & 기술·지역/주요 국가별 내역, 경쟁 환경, 주요 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 서론

제2장 요약·하이라이트

제3장 임상 개요

  • 암의 정의
  • 암의 리스크 요인·원인
  • 일반적인 암치료
  • 암의 의료 부담·관련 비용

제4장 암의 유형

  • 폐암
  • 비소세포폐암(NSCLC)
  • 소세포폐암(SCLC)
  • 기타 폐암
  • 방광암
  • 유방암
  • 자궁경부암
  • 대장암
  • 신장암
  • 백혈병
  • 림프종
  • 다발성 골수종
  • 간암
  • 흑색종
  • 뇌종양
  • 난소암
  • 전립선암
  • 위암

제5장 암의 역학

  • 역학 동향 : 암 유형·부위별
  • 세계의 암 발생률
  • 세계의 암 유병률
  • 세계의 암 사망률
  • 역학 동향 : 지역별

제6장 주요 출시 제품

  • 모노클로널 항체
  • 백신
  • CAR-T세포 치료

제7장 임상시험·파이프라인

  • 암 임상시험의 개요
  • 주요 파이프라인약 : 기업별
  • 주요 파이프라인약 개요
  • Penpulimab

제8장 COVID-19의 영향

제9장 시장 분석·예측 : 제품·기술별

  • 모노클로널 항체
  • CART 세포치료
  • 암백신

제10장 시장 분석·예측 : 지역별

  • 북미
  • 미국
  • 캐나다
  • 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 기타 지역

제11장 시장 전망 : 과제·동향

  • Medicare의 보장 범위·암치료의 상환
  • 암 생물제제의 가격 전략
  • 항암제 비용
  • 맞춤형 의료
  • 바이오시밀러의 개요
  • 바이오시밀러와 항암제 비용
  • 인도와 중국의 바이오시밀러
  • 바이오시밀러의 장벽
  • 유럽의 바이오시밀러
  • 바이오시밀러에 관한 문제
  • 데이터 보호 기간
  • 바이오의약품과 바이오 제네릭의 차이
  • 바이오시밀러와 환자 안전성

제12장 경쟁 구도

  • 경쟁 개요
  • 경쟁 점유율 분석
  • 주요 M&A
  • 주요 라이선싱 계약

제13장 기업 개요

  • AMGEN INC.
  • ASTRAZENECA
  • BRISTOL MYERS SQUIBB
  • ELI LILLY AND CO.
  • GENMAB
  • GILEAD SCIENCES INC.
  • GLAXOSMITHKLINE
  • JANSSEN PHARMACEUTICALS INC.
  • MERCK & CO.
  • NOVARTIS
  • PFIZER INC.
  • ROCHE(F. HOFFMANN-LA ROCHE AG)

제14장 부록 : 두자어

KSA 21.10.13

List of Tables

  • Summary Table A : Global Market for Cancer Biologics, by Product Type, Through 2026
  • Summary Table B : Global Market for Cancer Biologics, by Region, Through 2026
  • Table 1 : Global High BMI-Related Cancer Deaths and DALYs, 2017
  • Table 2 : National Expenditure Estimates for Cancer Care, by Cancer Type, 2015 vs. 2020
  • Table 3 : NSCLC Treatments
  • Table 4 : SCLC Treatments
  • Table 5 : Bladder Cancer Treatments
  • Table 6 : Breast Cancer Treatments
  • Table 7 : Cervical Cancer Treatments
  • Table 8 : Colorectal Cancer Treatments
  • Table 9 : Kidney Cancer Treatments
  • Table 10 : Leukemia Treatments
  • Table 11 : NHL Treatments
  • Table 12 : Multiple Myeloma Treatments
  • Table 13 : Liver Cancer Treatments
  • Table 14 : Melanoma Treatments
  • Table 15 : Brain Cancer Treatments
  • Table 16 : Ovarian Cancer Treatments
  • Table 17 : Prostate Cancer Treatments
  • Table 18 : Stomach Cancer Treatments
  • Table 19 : Global Cancer Incidence, by Cancer Type/Site, 2020
  • Table 20 : Global Cancer Mortality, by Cancer Type/Site, 2020
  • Table 21 : Estimated Number of New Cancer Cases in the U.S., by Cancer Type/Site and Sex, 2021
  • Table 22 : Estimated Number of Cancer Deaths in the U.S., by Cancer Type/Site and Sex, 2021
  • Table 23 : Comprehensive List of FDA-Approved Monoclonal Antibodies
  • Table 24 : Rituxan (Rituximab) Drug Profile
  • Table 25 : Avastin Drug Profile
  • Table 26 : Herceptin Drug Profile
  • Table 27 : Erbitux Drug Profile
  • Table 28 : Erbitux Approvals, by Year
  • Table 29 : Opdivo Drug Profile
  • Table 30 : Opdivo: Recent FDA Approvals and Regulatory Updates
  • Table 31 : Keytruda: Recent FDA Approvals and Regulatory Updates
  • Table 32 : Darzalex Drug Profile
  • Table 33 : Darzalex: FDA Approvals and Regulatory Updates
  • Table 34 : Perjeta Drug Profile
  • Table 35 : Imfinzi Drug Profile
  • Table 36 : Tecentiq Drug Profile
  • Table 37 : Tecentriq: FDA Approvals and Regulatory Updates
  • Table 38 : Xgeva Drug Profile
  • Table 39 : Kadcyla Drug Profile
  • Table 40 : Yervoy Drug Profile
  • Table 41 : Yervoy: Recent FDA Approvals and Regulatory Updates
  • Table 42 : Trodelvy Drug Profile
  • Table 43 : Blenrep Drug Profile
  • Table 44 : Jemperli Drug Profile
  • Table 45 : Zynlonta Drug Profile
  • Table 46 : Rybrevant Drug Profile
  • Table 47 : Sarclisa Drug Profile
  • Table 48 : Phesgo Drug Profile
  • Table 49 : Monjuvi Drug Profile
  • Table 50 : Provenge Drug Profile
  • Table 51 : Provenge: Key Product Highlights
  • Table 52 : Gardasil/Gardasil 9 Drug Profile
  • Table 53 : Gardasil/Gardasil 9: FDA-Approved Cancer Indications by Sex
  • Table 54 : Sales Statistics of Key Cancer Biologics, by Leading Manufacturers, 2018-2020
  • Table 55 : Number of Clinical Trials, by Cancer Type/Site and Phase, 2021
  • Table 56 : List of Selected Key Pipeline Cancer Biologics
  • Table 57 : Penpulimab Drug Profile
  • Table 58 : Sintilimab (Tyvyt) Drug Profile
  • Table 59 : Toripalimab Drug Profile
  • Table 60 : Tisotumab Vedotin Drug Profile
  • Table 61 : Retifanlimab Drug Profile
  • Table 62 : Glofitamab Drug Profile
  • Table 63 : Tiragolumab Drug Profile
  • Table 64 : Mosunetuzumab Drug Profile
  • Table 65 : Canakinumab Drug Profile
  • Table 66 : Datopotamab Deruxtecan Drug Profile
  • Table 67 : Reported COVID-19 Cases and Deaths, by Country, May 2021
  • Table 68 : Global Market for Cancer Biologics, by Product Type, Through 2026
  • Table 69 : List of Key Target Sites for Monoclonal Antibodies
  • Table 70 : Global Market for Monoclonal Antibodies to Treat Cancer, by Region, Through 2026
  • Table 71 : Global Market for CAR T-Cell Therapy for Cancer, by Region, Through 2026
  • Table 72 : Global Market for Cancer Vaccines, by Region, Through 2026
  • Table 73 : Global Market for Cancer Biologics, by Region, Through 2026
  • Table 74 : North American Market for Cancer Biologics, by Product Type, Through 2026
  • Table 75 : Key FDA Approved Novel Biologics, 2020 and 2021
  • Table 76 : Canada: Cancer Incidence, Mortality and Survival Estimates, by Cancer Type/Site, 2020
  • Table 77 : Key EMA Approved Novel Biologics, 2020 and 2021
  • Table 78 : European Market for Cancer Biologics, by Product Type, Through 2026
  • Table 79 : U.K.: Cancer Incidence and Mortality, by Cancer Type/Site, 2020
  • Table 80 : Germany: Cancer Incidence and Mortality, by Cancer Type/Site, 2020
  • Table 81 : France: Cancer Incidence and Mortality, by Cancer Type/Site, 2020
  • Table 82 : Italy: Cancer Incidence and Mortality, by Cancer Type/Site, 2020
  • Table 83 : Spain: Cancer Incidence and Mortality, by Cancer Type/Site, 2020
  • Table 84 : Asia-Pacific Market for Cancer Biologics, by Product Type, Through 2026
  • Table 85 : Japan: Cancer Incidence, Mortality and Survival Estimates, by Cancer Type/Site, 2020
  • Table 86 : Key Approved Novel Cancer Biologics by Japanese MHLW, 2020-2021
  • Table 87 : China: Cancer Incidence and Mortality, by Cancer Type/Site, 2020
  • Table 88 : Key Approved Novel Cancer Biologics by Chinese NMPA, 2019 and 2020
  • Table 89 : India: Cancer Incidence and Mortality, by Cancer Type/Site, 2020
  • Table 90 : Australia: Cancer Incidence, Mortality and Survival Estimates, by Cancer Type/Site, 2020
  • Table 91 : Rest of the World Market for Cancer Biologics, by Product Type, Through 2026
  • Table 92 : Key Federal Health Insurance Programs in the U.S.
  • Table 93 : Top Mergers and Acquisitions in the Global Cancer Therapeutics Market, 2019-2020
  • Table 94 : Top Licensing Deals of Cancer Drugs, 2019-2020
  • Table 95 : Amgen: Key Cancer Biologics Product Portfolio
  • Table 96 : AstraZeneca: Key Cancer Biologics Product Portfolio
  • Table 97 : Bristol Myers Squibb: Key Cancer Biologics Product Portfolio
  • Table 98 : Eli Lilly and Co.: Key Cancer Biologics Product Portfolio
  • Table 99 : Genmab: Key Cancer Biologics Product Portfolio
  • Table 100 : Gilead Sciences: Key Cancer Biologics Product Portfolio
  • Table 101 : GlaxoSmithKline: Key Cancer Biologics Product Portfolio
  • Table 102 : Janssen Pharmaceuticals: Key Cancer Biologics Product Portfolio
  • Table 103 : Merck& Co.: Key Cancer Biologics Product Portfolio
  • Table 104 : Novartis: Key Cancer Biologics Product Portfolio
  • Table 105 : Pfizer Inc.: Key Cancer Biologics Product Portfolio
  • Table 106 : Roche: Key Cancer Biologics Product Portfolio
  • Table 107 : Acronyms Used in This Report

List of Figures

  • Summary Figure A : Global Market Shares of Cancer Biologics, by Product Type, 2020
  • Summary Figure B : Global Market Shares of Cancer Biologics, by Region, 2020
  • Figure 1 : Global Tobacco Consumption Population, by Sex and Country, 2019
  • Figure 2 : Global Incidence of Alcohol-Attributable Cancers, by Cancer Type and Sex
  • Figure 3 : Share of Diagnosed Population of Infections-Attributable to Cancers, by Type, 2018
  • Figure 4 : Cancers Attributable to UV Radiation Exposure, by Region and Age Group, 2012
  • Figure 5 : Productivity Losses Due to Cancer Attributed to Premature Deaths in Emerging Economies, 2017
  • Figure 6 : U.S. National Cancer Costs, Projections and Trends, 2015-2030
  • Figure 7 : Global Cancer Incidence, by Sex and Cancer Type/Site, 2020
  • Figure 8 : Global Cancer Incidence, by Region, 2020
  • Figure 9 : Global Cancer Incidence Trends, by Cancer Type/Site, 2020-2030
  • Figure 10 : Global Cancer Prevalence by Cancer Type/Site and Sex, 2020
  • Figure 11 : Avastin: Global Product Revenue, 2018-2020
  • Figure 12 : Herceptin: Global Product Revenue, 2018-2020
  • Figure 13 : Erbutix: Global Product Revenue, 2019 and 2020
  • Figure 14 : Opdivo: Global Product Revenue, 2018-2020
  • Figure 15 : Keytruda: Global Product Revenue, 2018-2020
  • Figure 16 : Darzalex: Global Product Revenue, 2018-2020
  • Figure 17 : Perjeta: Global Product Revenue, 2018-2020
  • Figure 18 : Imfinzi: Global Product Revenue, 2018-2020
  • Figure 19 : Tecentriq: Global Product Revenue, 2018-2020
  • Figure 20 : Xgeva: Global Product Revenue, 2018-2020
  • Figure 21 : Kadcyla: Global Product Revenue, 2018-2020
  • Figure 22 : Yervoy: Global Product Revenue, 2018-2020
  • Figure 23 : Gardasil and Cervarix: Comparative Global Sales Trend, 2010-2020
  • Figure 24 : Heplisav-B: Global Net Product Revenue, 2018-2020
  • Figure 25 : Global Market Shares of Cancer Biologics, by Product Type, 2020
  • Figure 26 : Global Market for Cancer Monoclonal Antibodies, 2020-2026
  • Figure 27 : Number of Approved Cancer Monoclonal Antibodies, by Year, 2010-2020
  • Figure 28 : Comparison of Approved Indications for Matrix to CAR T-Cell Therapies
  • Figure 29 : Global Market for CAR T-Cell Therapies, 2020-2026
  • Figure 30 : Product Revenue of Key CAR T-Cell Therapy (Yescarta), by Region, 2018-2020
  • Figure 31 : Global Market for Cancer Vaccines, 2020-2026
  • Figure 32 : Global Market for Cancer Biologics, by Region, 2020-2026
  • Figure 33 : North American Market Shares of Cancer Biologics, by Product Type, 2020
  • Figure 34 : U.S. Market for Cancer Biologics, 2020-2026
  • Figure 35 : U.S. Leading Sites of New Cancer Incidence and Deaths, 2021
  • Figure 36 : Canadian Market for Cancer Biologics, 2020-2026
  • Figure 37 : European Market Shares of Cancer Biologics, by Product Type, 2020
  • Figure 38 : U.K. Market for Cancer Biologics, 2020-2026
  • Figure 39 : German Market for Cancer Biologics, 2020-2026
  • Figure 40 : French Market for Cancer Biologics, 2020-2026
  • Figure 41 : Italian Market for Cancer Biologics, 2020-2026
  • Figure 42 : Spanish Market for Cancer Biologics, 2020-2026
  • Figure 43 : Asia-Pacific Market Shares of Cancer Biologics, by Product Type, 2020
  • Figure 44 : Japanese Market for Cancer Biologics, 2020-2026
  • Figure 45 : Chinese Market for Cancer Biologics, 2020-2026
  • Figure 46 : Indian Market for Cancer Biologics, 2020-2026
  • Figure 47 : Australian Market for Cancer Biologics, 2020-2026
  • Figure 48 : Distribution of Cancer Care Spending in the U.S., by Treatment Cost, 2018
  • Figure 49 : Illustration of Traditional vs. PPM Based Model for Cancer Treatment
  • Figure 50 : Global Market Shares of Cancer Biologics, by Manufacturer, 2020
  • Figure 51 : Amgen: Annual Revenue, 2016-2020
  • Figure 52 : AstraZeneca: Annual Revenue, 2016-2020
  • Figure 53 : Bristol Myers Squibb: Annual Revenue, 2016-2020
  • Figure 54 : Bristol Myers Squibb: Revenue Share, by Geography, 2016-2020
  • Figure 55 : Eli Lilly and Co.: Annual Revenue, 2016-2020
  • Figure 56 : Eli Lilly and Co.: Revenue Share, by Therapy Area, 2020
  • Figure 57 : Genmab: Annual Revenue, 2016-2020
  • Figure 58 : Gilead Sciences: Annual Revenue, 2016-2020
  • Figure 59 : GlaxoSmithKline: Annual Revenue, 2016-2020
  • Figure 60 : GlaxoSmithKline: Revenue Share, by Business Segment, 2020
  • Figure 61 : Johnson & Johnson: Annual Revenue, 2016-2020
  • Figure 62 : Johnson & Johnson: Revenue Share, by Segment, 2020
  • Figure 63 : Merck & Co.: Annual Revenue, 2016-2020
  • Figure 64 : Novartis: Annual Revenue, 2016-2020
  • Figure 65 : Pfizer Inc.: Annual Revenue, 2016-2020
  • Figure 66 : Pfizer Inc.: Annual Revenue Share, by Geography, 2018-2020
  • Figure 67 : Roche: Annual Revenue, 2016-2020
  • Figure 68 : Roche: Revenue Share, by Therapy Area (Pharma Division), 2020

Highlights:

The global cancer biologics market should reach $143.0 billion by 2026 from $77.5 billion in 2021 at a compound annual growth rate (CAGR) of 13.0% for the forecast period of 2021 to 2026.

The monoclonal antibodies segment of the global cancer biologics market is expected to grow from $68.0 billion in 2021 to $124.1 billion in 2026 at a CAGR of 12.8% for the forecast period of 2021 to 2026.

The CAR T-cell therapy segment of the global cancer biologics market is expected to grow from $1.5 billion in 2021 to $7.3 billion in 2026 at a CAGR of 37.5% for the forecast period of 2021 to 2026.

Report Scope:

This report provides an update on BIO048C Biological Therapies for Cancer: Technologies and Global Markets. It reviews global markets for biologic therapeutics for cancer and forecasts trends for the use of biologics and cancer treatments through 2026. It discusses important biologics, market share by cancer type, products on the market, market share by company and statistical information for cancer types prevalent globally. It also includes current issues and trends affecting the industry, as well as factors influencing demand. The report covers biological products in development, biological products in clinical trials, and currently marketed and late-stage development biologic cancer products.

The market and sales data for recent years give strong support for research and development (R&D) programs and the move toward biologic treatment for cancer, as well as within biologics toward human monoclonal antibodies, vaccines and CAR T-cell therapies. The biologic drug classes discussed in this report with special focus on cancer treatment are -

  • Monoclonal antibodies.
  • Vaccines.
  • CAR T-cell therapies.

The following approaches to cancer therapeutics are excluded in the report -

  • Chemotherapy.
  • Alkylating agents.
  • Antimetabolites.
  • Cytotoxic agents.
  • Plant derivatives and hormone therapy corticosteroids.
  • Hormone antagonists/antagonists aromatase inhibitors.
  • Radiation therapy.
  • Adjunctive and Supportive therapy.
  • Interferons and Interleukins.
  • Other immunostimulants.
  • Biological therapies for the treatment of other diseases will not be addressed in this report.

The report also covers biological products in development, biological products in clinical trials, and currently marketed and late-stage development biologic cancer products, including -

  • Treatment trends and sales patterns across major cancer indications for U.S., Europe (France, Germany, Italy, Spain, the U.K.), Asia-Pacific (Japan, China, India, and Australia) and the rest of the world.
  • Market performance of major pharmaceutical companies.
  • Sales of leading cancer products across major indications from 2018 to 2020.
  • Biosimilars and their impact on currently marketed cancer biotherapeutics.
  • Competitor landscape and share analysis.

This updated report includes the following new information -

  • The latest version of the report provides elaborated information of cancer biologics market at a regional level. The current report provides regional and country-level market segmentation for the U.S., Europe (France, Germany, Italy, Spain, the U.K.), Asia-Pacific (Japan, China, India, and Australia) and the rest of the world.
  • The latest version of the report provides elaborated information of competitor landscape and company share analysis.
  • The latest version of the report also provides elaborated information on the novel CAR T-cell therapies.

Report Includes:

  • 29 data tables and 80 additional tables
  • An updated review of the global markets of biological therapies for cancer treatment and related technologies
  • Analyses of the global market trends, with data from 2020, estimates for 2021-2025, and projections of compound annual growth rates (CAGRs) through 2026
  • Estimation of the market size and revenue forecast for cancer biologics market and its sub-segments, and corresponding market share analysis by product type, cancer type, and geographic region
  • Coverage of biological products in development, biological products in clinical trials, and currently marketed and late-stage development biologic cancer products
  • Discussion of biological therapies products available in the market, industry structure, cancer markets in newly emerging therapeutics, and analysis of biosimilars drugs and their impact on the market
  • Review of cancer statistics and epidemiology insights and SWOT analysis of various cancer biotherapeutics present in the market
  • A look at major issues and trends with relate to the R&D of more effective cancer treatment, and new cancer therapeutics in development, and outlook on cancer clinical trials
  • Key marketed drugs and recent approvals, sales statistics and past performance of the top selling biologics, and insight into their patent expiries
  • Insight into the growth development strategies of the key market players operating within the global market; their key competitive landscape and company share analysis
  • Descriptive company profiles of the leading market participants, including Amgen Inc., Eli Lilly and Co., GlaxoSmithKline, Merck & Co. Inc., and Pfizer Inc.

Table of Contents

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • What's New in This Update
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Clinical Overview

  • Definition of Cancer
  • Risk Factors for and Causes of Cancer
  • Tobacco Use
  • Alcohol Abuse and Cancer Statistics
  • Obesity and Cancer Statistics
  • Infectious Diseases and Cancer
  • Inherited Genes: Diseases and Cancer
  • Sun, Ultraviolet Radiation and Cancer
  • Hormones and Cancer
  • Overview of Common Cancer Treatments
  • Surgery
  • Chemotherapy
  • Radiation Therapy
  • Hormone Therapy
  • Targeted Therapy and Immunotherapy
  • Overview of Cancer Burden and Related Costs

Chapter 4 Cancer Types

  • Lung Cancer
  • Overview
  • Non-small-Cell Lung Cancer (NSCLC)
  • Small-Cell Lung Cancer (SCLC)
  • Other Lung Cancers
  • Treatments
  • Bladder Cancer
  • Overview
  • Treatments
  • Breast Cancer
  • Overview
  • Common Breast Cancer Mutations
  • Treatments
  • Cervical Cancer
  • Overview
  • Treatments
  • Colorectal Cancer
  • Overview
  • Treatments
  • Kidney Cancer
  • Treatments
  • Leukemia
  • Overview
  • Treatment
  • Lymphoma
  • Overview
  • Treatment
  • Multiple Myeloma
  • Overview
  • Treatments
  • Liver Cancer
  • Overview
  • Treatments
  • Melanoma
  • Overview
  • Treatments
  • Brain Cancer
  • Overview
  • Treatments
  • Ovarian Cancer
  • Treatments
  • Prostate Cancer
  • Treatments
  • Stomach Cancer

Chapter 5 Cancer Epidemiology

  • Epidemiology by Cancer Type/Site
  • Global Cancer Incidence
  • Global Cancer Prevalence, 2020
  • Global Cancer Mortality Overview
  • Cancer Epidemiology by Region
  • Europe
  • North America
  • Asia-Pacific
  • Rest of the World

Chapter 6 Key Marketed Products

  • Current Drugs and Recent Approvals
  • Monoclonal Antibodies
  • Vaccines
  • CAR T-Cell Therapies
  • Sales Statistics of Selected Key Biologics

Chapter 7 Cancer Clinical Trials and Pipeline Biologics

  • Overview of Cancer Clinical Trials
  • Key Pipeline Drugs by Company
  • Key Pipeline Drug Profiles
  • Penpulimab

Chapter 8 Impact of COVID-19 Pandemic on the Market for Cancer Biologics

  • Overview
  • Current Outlook
  • Impact of COVID-19 on Cancer Care
  • Delay in Elective Surgical Procedures
  • Trade Restrictions and Supply Disruptions

Chapter 9 Market Breakdown by Product and Technology

  • Monoclonal Antibodies
  • Market Overview
  • Market Size and Forecast
  • Market Segmentation by Geography
  • CAR T-Cell Therapy
  • Market Overview
  • Market Size and Forecast Analysis
  • Market Segmentation by Geography
  • Cancer Vaccines
  • Market Overview
  • Market Size and Forecast Analysis
  • Market Segmentation by Geography

Chapter 10 Market Breakdown by Region

  • Global Market Overview
  • North America
  • United States
  • Canada
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of the World

Chapter 11 Cancer Biologics Market Outlook: Issues and Trends

  • Medicare Coverage and Reimbursement for Cancer Care
  • Pricing Strategies for Cancer Biologics
  • Cancer Drug Costs
  • Personalized Medicine
  • Overview of Biosimilars
  • Biosimilars and Costs of Cancer Drugs
  • Biosimilars in India and China
  • Hurdles For Biosimilars
  • Biosimilars in Europe
  • Issues with Biosimilars
  • Data Exclusivity Periods
  • Differences Between Biopharmaceuticals and Biogenerics
  • Biosimilars and Patient Safety

Chapter 12 Competitive Landscape

  • Competitive Overview
  • Competitive Share Analysis
  • Key Merger and Acquisitions in the Global Cancer Market
  • Key Licensing Deals in Global Cancer Market

Chapter 13 Company Profiles

  • AMGEN INC.
  • ASTRAZENECA
  • BRISTOL MYERS SQUIBB
  • ELI LILLY AND CO.
  • GENMAB
  • GILEAD SCIENCES INC.
  • GLAXOSMITHKLINE
  • JANSSEN PHARMACEUTICALS INC.
  • MERCK & CO.
  • NOVARTIS
  • PFIZER INC.
  • ROCHE (F. HOFFMANN-LA ROCHE AG)

Chapter 14 Appendix: Acronyms

Back to Top
전화 문의
F A Q